The composition of claim 9, wherein the calcipotriol or calcipotriol monohydrate is present in an amount between 0.001-0.05% w/w of the total composition, the betamethasone dipropionate is present in an amount between 0.0005-1% w/w of the total composition, and the pharmaceutically acceptable oily co-solvent is present in an amount between 0.1-10% w/w of the total composition. The composition of claim 15, wherein the straight C 8-24 alkanol is myristyl alcohol. The composition of claim 14, wherein (i) the straight C 8-24 alkanol is capryl alcohol, lauryl alcohol, cetyl alcohol, stearyl alcohol, or myristyl alcohol, (ii) the straight C 8-24 alkenol is oleyl alcohol or linoleyl alcohol, and/or (iii) the branched C 8-24 alkanol is a branched C 18-24 alkanol. The composition of claim 9, wherein the oily co-solvent comprises a straight or branched C 8-24 alkanol or alkenol. The composition of claim 12, wherein the isopropyl ester of a straight or branched chain C 10-18 alkanoic or alkenoic acid is isopropyl myristate, isopropyl palmitate, isopropyl isostearate, isopropyl linolate, or isopropyl monooleate. The composition of claim 9, wherein the oily co-solvent comprises an isopropyl ester of a straight or branched chain C 10-18 alkanoic or alkenoic acid. The composition of claim 10, wherein the compound of general formula I is polyoxypropylene-15-stearyl ether, polyoxypropylene-11-stearyl ether, polyoxypropylene-14-butyl ether, polyoxypropylene-10-cetyl ether, or polyoxypropylene-3-myristyl ether. H(OCH 2C(CH 3)H) xOR 1 wherein R 1 is a straight or branched chain C 1-20 alkyl, and x is an integer from 2 to 60 inclusive.The composition of claim 9, wherein the oily co-solvent comprises a compound of general formula I: The composition of claim 8, wherein the composition further comprises a pharmaceutically acceptable oily co-solvent. The composition of claim 1, wherein the pharmaceutically acceptable lipid carrier comprises petrolatum. The composition of claim 2, wherein the pharmaceutically acceptable propellant comprises dimethyl ether. The composition of claim 5, wherein the C 3-5 alkane is n-butane. The composition of claim 4, wherein the C 3-5 alkane is propane, isopropane, n-butane, isobutane, or mixtures thereof. The composition of claim 1, wherein the pharmaceutically acceptable propellant comprises a C 3-5 alkane. The composition of claim 2, wherein the composition further comprises a pharmaceutically acceptable lipophilic viscosity increasing ingredient. The composition of claim 1, wherein each gram of the composition, excluding any mass contributed by any pharmaceutically acceptable propellant, comprises 52.2 mcg of calcipotriol monohydrate and 0.643 mg betamethasone dipropionate. A sprayable, substantially anhydrous topical composition comprising calcipotriol or calcipotriol monohydrate, betamethasone dipropionate, a pharmaceutically acceptable propellant, present in amount between 45-95% w/w of the total composition, a pharmaceutically acceptable lipid carrier, present in an amount between 5-55% w/w of the total composition, and a pharmaceutically acceptable antioxidant, wherein the composition does not include propylene glycol, wherein visible crystals of the calcipotriol or calcipotriol monohydrate or the betamethasone dipropionate are not observed, as determined by polarized light microscopy, after storage of the composition for 12 months at about 25°
0 Comments
Leave a Reply. |